A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Cardiovascular Events

In brief

This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood pressure (SBP) 130 to 159 mmHg, in preventing major cardiovascular (CV) events and on global measures of physical, executive and cognitive function.

Key facts

Study ID

NCT01259297

Run by

Novartis Pharmaceuticals

People needed

2336

Starts

2011-01-01

Expected to finish

2012-11-01

Last updated by the study team

2014-04-08

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Systolic blood pressure 130 - 159 mmHg with any one of the following (1, 2 or 3):
• Men and women aged ≥ 65 years if they have at least one of the following: (secondary prevention) Coronary heart disease
• Previous myocardial infarction or
• Stable angina or unstable angina with documented multi-vessel coronary artery disease, > 50% stenosis in at least 2 major coronary arteries on coronary angiography, or positive stress test (ECG or nuclear perfusion scintogram), or
• Multi-vessel PCI, or
• Multi-vessel CABG surgery > 4 years prior to informed consent, or with recurrent angina or ischemia following surgery Stroke/TIA Previous documented stroke or documented TIA < 1 year before informed consent Peripheral artery disease
• Previous limb bypass surgery or percutaneous transluminal angioplasty, or
• Previous limb or foot amputation, or
• History of intermittent claudication, with an ankle:arm BP ratio ≤ 0.80 on at least one side, or significant peripheral artery stenosis (> 50%) documented by angiography or non-invasive testing
• Diabetes mellitus: High-risk diabetics with evidence of end-organ damage
• Men and women aged ≥ 65 years with no history of CVD, and with at least 1 CV risk factor (primary prevention):
• History of dyslipidemia, defined as LDL cholesterol > 3.5 mmol/L (135 mg/dL) or HDL< 1.3 mmol/L (50 mg/dL) in women or < 1.0 mmol/L (39 mg/dL) in men or total cholesterol/HDL ratio > 5
• History of current or recent smoking (regular tobacco use within 5 years)
• Abdominal adiposity defined as waist/hip ratio ≥ 0.90 in women and ≥ 0.95 in men
• History of dysglycemia defined as impaired fasting glucose (IFG - fasting plasma glucose 5.6 to 6.9 mmol/L [101 to 124 mg/dL]), or impaired glucose tolerance (IGT - fasting plasma glucose < 7 mmol/L [126 mg/dL] but 2 hour glucose 7.8 to 11.0 mmol/L [140 to 198 mg/dL]) or type 2 diabetes
• Renal dysfunction: eGFR< 60 ml/min/1.73m2 but > 30 ml/min/1.73m2 (MDRD formula) and/or microalbuminurea/macroalbuminurea
• Clinical evidence of left ventricular hypertrophy
• Men and women aged ≥ 70 years if they do not have any of the above (primary prevention)

You may not qualify if…

• Current treatment with aliskiren, an ACE-inhibitor, an ARB or an aldosterone antagonist and unable to discontinue this therapy in those without clinical vascular disease. Individuals with CVD or type 2 diabetes and/or renal dysfunction may receive an ACE-inhibitor or an ARB, but not both, contraindications to Aliskiren, Amlodipine or Hydrochlorothiazide.
• Use of both thiazide diuretic and amlodipine or another calcium channel blocker. Patients on only one of these two classes of drugs are eligible
• Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg)
• Symptomatic heart failure, requiring the use of loop diuretics
• Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve). Constrictive pericarditis. Complex congenital heart disease.
• Acute stroke < 3 months or TIA ≤ 7 days before informed consent, acute coronary syndrome < 1 months before informed consent
• Planned cardiac surgery or angioplasty < 3 months after informed consent or having had the procedure < 3 months before informed consent
• Severe renal impairment eGFR ≤ 30 ml/min/1.73m2 (MDRD formula); known renal artery stenosis ; serum potassium ≥ 5.3 mmol/L
• Chronic liver disease (i.e. cirrhosis, esophageal varices, portocaval shunt or persistent hepatitis) or abnormal liver function, i.e., alanine transaminase (ALT) or AST > 3x upper limit of normal (ULN)
• Concurrent treatment with cyclosporine or quinidine; chronic use of non-steroidal anti-inflammatory drug (NSAIDs) or cyclooxygenase-2 (COX 2) inhibitors in patients with eGFR < 60 ml/min/1.73m2 (MDRD formula)
• History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years regardless of whether there is evidence of local recurrence or metastases
• Other serious condition(s) likely to interfere with study participation or with the ability to complete the study. Significant psychiatric illness, senility, dementia, alcohol or substance abuse, which could impair the ability to provide informed consent and to adhere to the study procedures

Where it is running

• Novartis Investigative Site — Los Angeles, California, United States
• Novartis Investigative Site — Northridge, California, United States
• Novartis Investigative Site — Sylmar, California, United States
• Novartis Investigative Site — Tucker, Georgia, United States
• Novartis Investigative Site — Pocatello, Idaho, United States
• Novartis Investigative Site — Haverhill, Massachusetts, United States
• Novartis Investigative Site — St Louis, Missouri, United States
• Novartis Investigative Site — Westfiled, New York, United States
• Novartis Investigative Site — Winston-Salem, North Carolina, United States
• Novartis Investigative Site — Portland, Oregon, United States
• Novartis Investigative Site — Falls Church, Virginia, United States
• Novartis Investigative Site — Marshfield, Wisconsin, United States
• Novartis Investigative Site — Milwaukee, Wisconsin, United States
• Novartis Investigative Site — Buenos Aires, Buenos Aires, Argentina
• Novartis Investigative Site — Buenos Aires, Buenos Aires, Argentina
• Novartis Investigative Site — Buenos Aires, Buenos Aires, Argentina
• Novartis Investigative Site — Buenos Aires, Buenos Aires, Argentina
• Novartis Investigative Site — Ciudad Autonoma de Bs As, Buenos Aires, Argentina
• Novartis Investigative Site — Coronel Suárez, Buenos Aires, Argentina
• Novartis Investigative Site — Jenin, Buenos Aires, Argentina
• Novartis Investigative Site — Mar del Plata, Buenos Aires, Argentina
• Novartis Investigative Site — Merlo, Buenos Aires, Argentina
• Novartis Investigative Site — Quilmes, Buenos Aires, Argentina
• Novartis Investigative Site — San Nicolás de los Arroyos, Buenos Aires, Argentina
• Novartis Investigative Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.